JP2019501200A - 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス - Google Patents

後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス Download PDF

Info

Publication number
JP2019501200A
JP2019501200A JP2018535400A JP2018535400A JP2019501200A JP 2019501200 A JP2019501200 A JP 2019501200A JP 2018535400 A JP2018535400 A JP 2018535400A JP 2018535400 A JP2018535400 A JP 2018535400A JP 2019501200 A JP2019501200 A JP 2019501200A
Authority
JP
Japan
Prior art keywords
antibody
vegf
drug
aflibercept
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535400A
Other languages
English (en)
Japanese (ja)
Inventor
サミルクマール パテル，
サミルクマール パテル，
Original Assignee
クリアサイド バイオメディカル，インコーポレイテッド
クリアサイド バイオメディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリアサイド バイオメディカル，インコーポレイテッド, クリアサイド バイオメディカル，インコーポレイテッド filed Critical クリアサイド バイオメディカル，インコーポレイテッド
Publication of JP2019501200A publication Critical patent/JP2019501200A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2018535400A 2016-01-08 2017-01-09 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス Pending JP2019501200A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US62/276,543 2016-01-08
US201662324708P 2016-04-19 2016-04-19
US62/324,708 2016-04-19
PCT/US2017/012757 WO2017120601A1 (fr) 2016-01-08 2017-01-09 Méthodes et dispositifs pour le traitement de troubles oculaires postérieurs avec l'aflibercept et d'autres substances biologiques

Publications (1)

Publication Number Publication Date
JP2019501200A true JP2019501200A (ja) 2019-01-17

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535400A Pending JP2019501200A (ja) 2016-01-08 2017-01-09 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス

Country Status (9)

Country Link
EP (1) EP3400014A1 (fr)
JP (1) JP2019501200A (fr)
KR (1) KR20180101488A (fr)
CN (1) CN108778330A (fr)
AU (1) AU2017206114A1 (fr)
BR (1) BR112018013805A2 (fr)
CA (1) CA3010862A1 (fr)
MX (1) MX2018008469A (fr)
WO (1) WO2017120601A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
CN103327939B (zh) 2010-10-15 2017-05-24 科尼尔赛德生物医学公司 用于进入眼睛的装置
US20150258120A1 (en) 2012-11-08 2015-09-17 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
KR102282973B1 (ko) 2013-05-03 2021-07-27 클리어사이드 바이오메디컬, 인코포레이드 안구용 주사를 위한 장치 및 방법
EP3003454B1 (fr) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Appareil pour une administration de médicament à l'aide de multiples réservoirs
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
IL305537A (en) 2016-08-12 2023-10-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
EP3687464A4 (fr) * 2017-09-27 2021-09-29 REGENXBIO Inc. Traitement de maladies oculaires avec un fab anti-vegf à modification post-traductionnelle totalement humain
US11358949B2 (en) * 2017-12-20 2022-06-14 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
MA52570A (fr) 2018-05-10 2021-03-17 Regeneron Pharma Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
SG11202110789VA (en) * 2019-04-03 2021-10-28 Regenxbio Inc Gene therapy for eye pathologies
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
CA3160526A1 (fr) * 2019-11-11 2021-05-20 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Combinaison pharmaceutique et utilisation de celle-ci
CA3171479A1 (fr) * 2020-02-19 2021-08-26 Clearside Biomedical, Inc. Compositions comprenant de l'axitinib et methodes de traitement de troubles oculaires
WO2021257193A1 (fr) * 2020-06-15 2021-12-23 Opko Pharmaceuticals, Llc Formulations ophtalmiques topiques à base de liposomes chargés d'acétonide de triamcinolone en tant que thérapie primaire pour un œdème maculaire secondaire à une occlusion de la veine rétinienne ramifiée
MX2023013554A (es) * 2021-05-17 2023-11-29 Regeneron Pharma Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos.
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140114208A1 (en) * 2011-05-27 2014-04-24 Novartis Ag Method of treating vision disorders
CA2865132A1 (fr) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions et procedes pour administration oculaire d'un agent therapeutique
US20150258120A1 (en) * 2012-11-08 2015-09-17 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CA2933900A1 (fr) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Preparations et procedes servant a introduire de maniere ciblee des agents therapeutiques dans l'ƒil
US20180042765A1 (en) * 2014-06-17 2018-02-15 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders

Also Published As

Publication number Publication date
MX2018008469A (es) 2018-11-09
EP3400014A1 (fr) 2018-11-14
AU2017206114A1 (en) 2018-08-02
CN108778330A (zh) 2018-11-09
CA3010862A1 (fr) 2017-07-13
WO2017120601A1 (fr) 2017-07-13
KR20180101488A (ko) 2018-09-12
BR112018013805A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
JP6774340B2 (ja) 後眼部障害を処置するための方法およびデバイス
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
JP7082599B2 (ja) ヒト被験体における眼部障害の処置のための方法およびデバイス
US20220249517A1 (en) Compositions and methods for treating noninfectious uveitis